1997.-Because obesity, insulin resistance, and hyperlipidemia are often associated, and recent evidence suggests that the cytokine tumor necrosis factor-a (TNF) may influence the activity of insulin in various target tissues, the present study was designed to see whether TNF was also associated with the changes in lipid metabolism that lead to hyperlipidemia in the obese model of the Zucker rat. A polyclonal goat anti-rat TNF antibody was subcutaneously administered to Zucker rats for 4 days to block TNF actions.
The results indicate that none of the alterations in lipid metabolism seen in the obese animals were reversed by the anti-TNF treatment. This was the case for the lipogenic rate in liver and adipose tissue, the disposal of an exogenous
[14C]triolein load, adipose tissue lipoprotein lipase activity, and the hypertriglyceridemia. Measurements of lipolysis in adipose tissue slices from the anti-TNF-treated animals also did not show any significant effect of the treatment.
In conclusion, TNF does not seem to be involved in the abnormalities of lipid metabolism observed in the obese Zucker rat,.
adipose tissue in vitro, the cytokine decreases the activity of lipoprotein lipase (the enzyme responsible for the cleavage of triglyceride-rich lipoproteins and the subsequent entry of fatty acids into the tissue), an effect which seems to be due to a decreased synthesis of the enzyme (9). Administration of purified TNF to intact animals has also been shown to decrease the activity of the enzyme in epididymal fat after several hours (22, 26) . In this way, the cytokine contributes to the decrease in adipose tissue mass during catabolic states that eventually lead to cachexia. Indeed, the role of TNF as a key mediator of cachexia has been the object of intense study and debate (2, 30 status, the obese Zucker rat is also insulin resistant (shows a smaller than expected biological response to a given dose of insulin), this being particularly marked in relation to insulin-mediated glucose disposal by skeletal muscle (23).
Hotamisligil et al. (16) reported increased expression of the cytokine tumor necrosis factor-a mRNA in four different animal models of obesity (including the Zucker rat) with corresponding elevation of TNF protein, both locally and systemically. Interestingly, the neutralization of TNF by means of soluble TNF receptorimmunoglobulin G fusion protein resulted in a significant increase in the peripheral uptake of glucose in response to insulin (16). In relation to this, Lang et al. (17) showed that infusion of TNF into experimental animals results in decreased insulin-mediated glucose disposal by skeletal muscle. Recent work (15) has demonstrated that TNF participates in obesity-related systemic insulin resistance by inhibiting the insulin receptor tyrosine kinase activity in both skeletal muscle and adipose tissue, the two main tissues responsible for insulin-stimulated glucose uptake. Interestingly, insulin resistance and hyperlipidemia are both present in other pathological states associated with increased TNF production. Indeed, TNF has been implicated in the insulin-resistant state associated with infection (17) and cancer (19). In addition, TNF has also been involved in many abnormalities concerning lipid metabolism during both infection (12) and cancer (4, 8) .
In recent years, the role of tumor necrosis factor (TNF) in lipid metabolism (particularly white adipose tissue) has been the core of a plethora of investigations.
Thus the cytokine is known to be associated with the hyperlipidemia found in catabolic states such as sepsis, trauma, or cancer (8, 10, 12) .
With this in mind, the objective of the present investigation was to see whether by blocking TNF action (using a polyclonal goat antibody against rat TNF) it would be possible to reverse the abnormalities of lipid metabolism in the obese Zucker rat in a fashion similar to the reported relief of insulin resistance in muscle of obese animals (16). were determined 3 h after cytokine administration, as indicated below (Table 1) .
Obese Zucker rats received for four consecutive days daily (at 0900) subcutaneous injections of polyclonal goat antimurine TNF IgG preparation (anti-TNF, 25 mg/kg body wt) or of a nonimmune goat IgG (IgG). No significant differences were observed in daily food intake between the animals receiving the nonimmune IgG preparation and those receiving the anti-TNF treatment (Table 2 ). All the experiments were carried out at the end of the treatment with either anti-TNF or IgG. Plasma ZJVF assay. Plasma TNF was measured with the WEHI 164 subclone 13 cytotoxicity assay (7). Briefly, 5 X lo4 cells in RPM1 1640 containing 10% fetal calf serum (FCS), 1 mM L-glutamine, and 0.5 ug/ml actinomycin D were added to serially diluted samples in microtiter plates and were incubated for 20 h at 37°C and 5% C02. Cytotoxicity was assessed by measuring MTT-tetrazolium (3, [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) conversion to formazan at 550 nm (13). The limit of detection of the assay was 1 pg/ml. Radiolabeled probes were prepared by the random primer method (Boehringer). Ethidium bromide was used as a control of sample loading. Filters were exposed to X Omat AR-5 film (Kodak) at -70°C for 2-4 days and the films quantified by laser densitometry.
Statistics.
Results are expressed as means t SE for the number of individual observations indicated in each experiment. Statistical significances were determined by the Student's t-test.
RESULTS
To show a clear positive control for the in vivo action of the anti-TNF antibody, rats were injected with recombinant murine TNF-(x, and both adipose tissue LPL activity and plasma triacylglycerol concentration were assessed. Administration of the cytokine promoted a marked decrease in LPL activity, this being associated with an increase in plasma triacylglycerols (Table 1) . Anti-TNF treatment reversed the cytokine action, thus supporting its efficacy, in agreement with what has previously been reported (4,6).
The anti-TNF treatment had no effect on food intake, increase in body weight, or final weight ( Table 2) . The rates of lipogenesis in liver, WAT depots (epididymal, perirenal, and subcutaneous), and IBAT were also not significantly decreased by anti-TNF; in fact, there was tendency for increased rates (Table 3 ). The absorption, oxidation, and tissue deposition of an oral load of 14C-labeled lipid was similarly unchanged by anti-TNF (Table 4 ). The low rate of oxidation and high percentage of the load deposited in the carcass suggested that the activity of LPL in the adipose tissue mass was not altered by the treatment, and this was confirmed by direct measurements (Table 5 ). The anti-TNF did not significantly alter the concentrations of blood glucose or lactate or the plasma triacylglycerols, NEFA, or insulin (Table 5 ). The latter findings contrast with those of Hotamisligil et al. (15) , who reported that neutralization of TNF in obese Zucker rats resulted in a significant decrease in plasma free fatty acid and insulin concentrations with no changes in triglyceridemia. In vitro, the basal or stimulated rates of lipolysis by adipose tissue pieces were not altered by the anti-TNF treatment (Table 6 ). It has to be pointed out, however, that because only a single hormone concentration was tried, the possibility cannot be ruled out that TNF may still influence the sensitivity of insulin or isoproterenol in adipose tissue. Thus anti-TNF treatment for 4 days has no detectable effect on lipid metabolism in the Zucker rat, although we have shown that a similar protocol was effective in reversing the metabolic abnormalities in the cachectic tumor-bearing rat (4,6). The results presented in Fig. 1 clearly show the existence of TNF mRNA in WAT from Zucker rats, as previously reported (16). However, the circulating levels of the cytokine were relatively low: 4.1 + 0.5 pg/ml of plasma in the IgG-treated obese animals (n = 41, whereas no detectable TNF was present in the anti-TNF-treated animals. Anti-TNF treatment resulted in no changes in expression of TNF mRNA in adipose tissue.
DISCUSSION
The metabolic environment of the obese Zucker rat is characterized by a marked hyperlipidemia. However, the circulating lipid seems to be basically the result of a large increase in de novo production of fatty acids in the liver, which are subsequently exported as VLDL (18) 
